• Sign up to our Free Newsletter
  • Contact Us
  • Editorial Submission
Microbiome Times Magazine
  • Human Health
  • Finance
  • Drug Database
    • Login
    • About
  • Issue Archive
  • Advertise
  • Recruitment Marketing

Pharma & Human Health

Pharma & Human Health

Traces of bacteria inside brain tumors may affect tumor behavior

November 24, 2025 Microbiome Times

Researchers at The University of Texas MD Anderson Cancer Center have uncovered unexpected traces of bacteria within brain tumors. This discovery offers new insights into the environment in which brain tumors grow and sets the […]

Pharma & Human Health

Whitepaper: Oral Drug Delivery of Live Biotherapeutics: From Development to Clinical Trial with EUDRACAP® Select

November 19, 2025 Microbiome Times

Delivering live biotherapeutics orally remains one of the challenges in microbiome therapy. In this white paper, Evonik presents a real-world case study of how EUDRACAP® Select—a ready-to-fill enteric capsule—enabled the safe and targeted delivery of […]

Editor's Choice

Siolta Therapeutics Reports Positive Phase 2 Results from the ADORED Study

November 17, 2025 Microbiome Times

Siolta Therapeutics, a clinical-stage biotech company developing first-in-class live biotherapeutic products (LBPs), today announced positive top-line results from the Phase 2 ADORED study (Allergic Disease Onset pREvention stuDy) of STMC-103H, its lead investigational oral microbial […]

Editor's Choice

The OMNIgene™•VAGINAL device – Optimized solutions for vaginal microbiome studies

November 12, 2025 Heloise Breton, PhD

The women’s health gap refers to disparities in health outcomes and the limited research into conditions that exclusively affect women or affect them differently from men. This gap stems from the historic exclusion of females […]

Pharma & Human Health

Ferring Presents New Data Analyses for REBYOTA®

November 4, 2025 Microbiome Times

Ferring Pharmaceuticals shared an oral presentation last month detailing microbiome restoration from the Phase 3b CDI-SCOPE study among patients with recurrent C. difficile (C. diff) infection (CDI) who received REBYOTA® (fecal microbiota, live – jslm). This research was […]

Finance

Seres Therapeutics Receives Award of up to $3.6M from Carb-X to Develop Liquid Formulation of Ser-155

October 31, 2025 Microbiome Times

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, announced that CARB-X, a global non-profit partnership accelerating antibacterial products to address drug-resistant bacteria, will provide up to $3.6 million in additional non-dilutive funding to […]

Pharma & Human Health

Concerto Biosciences Announces Positive Topline Results from Phase 1b Clinical Trial of ENS-002 in Patients with Atopic Dermatitis

October 29, 2025 Microbiome Times

Concerto Biosciences®, a clinical-stage biotech company developing microbial products for therapeutics and consumer markets, today announced positive topline results from its first-in-human Phase 1b clinical trial evaluating ENS-002, a topical three-strain live biotherapeutic product for […]

Pharma & Human Health

Scientists develop a way to track donor bacteria after fecal microbiota transplants

October 27, 2025 Microbiome Times

Researchers at the Icahn School of Medicine at Mount Sinai and their collaborators have developed a new technology to track beneficial bacteria after fecal microbiota transplants (FMT). The approach provides a detailed view of how […]

Pharma & Human Health

Discovery of hundreds of new human gut viruses provides a new approach to studying the gut microbiome

October 17, 2025 Microbiome Times

Hundreds of new viruses living inside bacteria within our gut have been discovered in an international study led by Professor Jeremy J. Barr from Monash University’s School of Biological Sciences and Associate Professor Sam Forster […]

Animal Health

Phagos Raises €25m Series A

October 10, 2025 Microbiome Times

Founded in 2021, Phagos is ushering in a new era in the fight against bacterial disease with bacteriophages, a powerful alternative to antibiotics. Thanks to an unprecedented regulatory breakthrough and a discovery platform combining microbiology […]

Pharma & Human Health

New collaborations emerge at Gut-Immune-Brain Axis (GIBA) Network+ launch event

October 8, 2025 Microbiome Times

A pioneering research network to unlock the link between gut, immune and brain health has taken its first steps at a launch event on September 22 in Southampton. Researchers and stakeholders from across the UK […]

Posts navigation

« 1 2 3 4 … 87 »

Sign Up to Free Newsletter

QIAGEN WEBINAR SERIES – REGISTER HERE

NEW WHITEPAPER: ORAL DELIVERY OF LIVE BIOTHERAPEUTIC PRODUCTS:

Editor’s Choice

  • LACTIN-V: A Promising Live Biotherapeutic for Recurrent Bacterial Vaginosis
    May 1, 2026
  • Lactic Acid’s Untapped Potential to Optimise the Vaginal Microbiota and Mucosal Environment
    April 8, 2026
  • Multi-strain probiotic therapy shows promise in preventing bacterial vaginosis recurrence
    March 24, 2026
  • Microbiotica Announces Impressive Results in its Phase 1b Trial of MB310 in Ulcerative Colitis
    February 11, 2026
  • Immunity as a Lifestyle Priority
    January 30, 2026
sign up

Sign up to the Microbiome Times newsletter